Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Blended Eclectic Programme to Improve Community Preparedness for Acute Myocardial Infarction (BE-Prepared)

13. November 2026 aktualisiert von: Dr. Polly Wai-Chi Li, The University of Hong Kong

Enhancing Chest Pain Centre Services With the Blended Eclectic Programme to Improve Community Preparedness for Acute Myocardial Infarction: An Effectiveness-implementation Hybrid Study

Coronary artery disease (CAD) is the leading cause of death and disability worldwide, and acute myocardial infarction (AMI, commonly known as heart attack) is its most severe and life-threatening form. In a heart attack, the time from symptoms onset to the receipt of reperfusion therapy to restore blood flow ("total ischaemic time") strongly influences how much heart muscle is saved and whether the patient survives. The longer the delay, the worse the outcome.

Despite effort to reduce in-hospital delay through establishment of chest pain centres, a critical gap remains. The time taken by patients to recognise symptoms and seek care during the prehospital stage accounts for the largest proportion of total ischaemic time. This study proposes the "Blended Eclectic Programme for Optimising Community Preparedness (BE-Prepared)" to improve timely care-seeking behaviours among CAD patients and the general public, ultimately reducing prehospital delays and improving AMI patient outcomes in Hong Kong. This programme consists of two components: a community-based health education component and a narrative intervention for CAD patients.

It is hypothesised that CAD patients who receive the BE-Prepared programme, compared with those receiving usual care, will show greater improvements in behavioural intention to seek care for AMI symptoms, better AMI knowledge, and fewer perceived barriers to care-seeking. It is further hypothesised that CAD patients who receive the programme will report a shorter onset-to-door time, be more likely to use an ambulance, and have reduced in-hospital stays and fewer 30-day major adverse cardiac and cerebrovascular events following an AMI episode relative to the control group.

The study uses a type 2 effectiveness-implementation hybrid design, combining a randomised controlled trial with a qualitative study to evaluate both whether the programme works and how it can be integrated into routine practice. Adults aged ≥18 with confirmed CAD but no prior AMI will be recruited from three major Hong Kong public hospitals and randomly assigned 1:1 to BE-Prepared or usual care. Outcomes will be assessed at baseline, 3 months, and 12 months, with 12-month monitoring for acute coronary events, guided by the RE-AIM framework. Healthcare providers will join SWOT workshops and selected patients will be interviewed. If effective, BE-Prepared could close a critical gap in current services, reducing prehospital delay and improving AMI outcomes in Hong Kong.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Acute myocardial infarction (AMI) is a highly time-sensitive emergency in which treatment delay is associated with larger infarct size, more complications, and higher mortality. A key prognostic determinant is total ischaemic time, the interval from symptom onset to reperfusion therapy. Although clinical guidelines recommend a system delay of under 60 minutes from diagnosis to wire crossing during primary percutaneous coronary intervention, and Hong Kong is establishing chest pain centres (CPCs) from July 2025 to reduce in-hospital delays, the prehospital interval remains the largest contributor to total ischaemic time.

Care-seeking is a complex perceptual-cognitive process requiring accurate symptom attribution, perceived susceptibility to a life-threatening event, and the influence of contextual factors such as competing responsibilities and external prompts. Therefore, this study proposes a comprehensive, theory-driven approach-the Blended Eclectic programme for optimising community Preparedness (BE-Prepared)-to improve timely care-seeking behaviours among CAD patients and the general public.

The study adopts a type 2 effectiveness-implementation hybrid design, simultaneously assessing clinical effectiveness and implementation with equal priority. It comprises a prospective, assessor-blinded, two-arm randomised controlled trial (RCT) to evaluate the effects of the BE-Prepared programme among CAD patients, and a qualitative study to gather stakeholder insights on the implementation process. Following written informed consent, participants will be randomly allocated in a 1:1 ratio to the intervention group (BE-Prepared programme) or the control group (usual care). The BE-Prepared programme consists of two components: a community-based health education component and a narrative intervention for CAD patients. Allocation will be concealed. A research assistant will ask participants to select a sealed envelope corresponding to a computer-generated random number, assigning them to the intervention or control group.

CAD participants will be recruited from three major public hospitals providing emergency cardiac care. Recruitment will be publicised through social media and the patient self-help organisation. Eligible participants will receive a verbal explanation supplemented by an information sheet and must sign an informed consent form prior to data collection, receiving a signed copy. A baseline assessment lasting approximately 30 minutes will be scheduled. Healthcare providers for the SWOT analysis will be recruited from cardiac wards at three major hospitals and will attend a 1.5-hour SWOT workshop to identify barriers and facilitators to integrating BE-Prepared into routine CAD care. The sample size was calculated based on prior findings from a theory-based narrative intervention developed by the project team for AMI survivors, in which effect sizes for attitudes and beliefs regarding care-seeking were 0.34 and 0.41 at 12 months post-intervention. Using PASS 2021, 175 participants per arm provide 80% power at a 5% two-sided significance level to detect an effect size of 0.30. Allowing for a 20% dropout rate, 438 participants will be recruited (219 per group) for the two-arm RCT, together with 45 healthcare professionals for the SWOT analysis across the participating hospitals.

Descriptive statistics will summarise reach, adoption, and maintenance data. Baseline homogeneity between study groups will be assessed using the independent t-test, chi-square test, or Fisher's exact test as appropriate. Generalised estimating equations (GEE) will compare changes in outcome variables across T0, T1, and T2 between groups, accounting for intra-correlated repeated measures and accommodating randomly missing data due to incomplete attendance or dropout. Between-group differences in symptom onset-to-door (O2D) time and ambulance use among participants experiencing an AMI by T2 will be assessed using the independent t-test and chi-square test. A generalised linear model with an appropriate link function will compare major adverse cardiovascular and cerebrovascular event (MACCE) episodes, hospital readmissions, and length of stay. Analyses will follow an intention-to-treat approach; all tests will be two-sided with p < 0.05 considered statistically significant, conducted in IBM SPSS 29.0. Qualitative interview data will be audio-recorded, transcribed verbatim, and cross-checked against the original recordings by the lead principal investigator. Content analysis will code participants' perceptions, engagement experience, and the acceptability of the intervention, and will explore how and why the programme influences care-seeking behaviours and intentions. To enhance trustworthiness, an audit trail will be maintained and two investigators will independently code the qualitative data.

Studientyp

Interventionell

Einschreibung (Geschätzt)

438

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Dr. Polly Wai-Chi Li, PhD
  • Telefonnummer: +852 39176686
  • E-Mail: pwcli@hku.hk

Studienorte

      • Hong Kong, Hongkong
        • Queen Mary Hospital
        • Kontakt:
          • Dr. Polly Wai-Chi Li, PhD
          • Telefonnummer: +852 39176686
          • E-Mail: pwcli@hku.hk
      • Hong Kong, Hongkong
        • Prince of Wales Hospital
        • Kontakt:
          • Dr. Polly Wai-Chi Li, PhD
          • Telefonnummer: +852 39176686
          • E-Mail: pwcli@hku.hk
      • Hong Kong, Hongkong
        • Queen Elizabeth Hospital
        • Kontakt:
          • Dr. Polly Wai-Chi Li, PhD
          • Telefonnummer: +852 39176686
          • E-Mail: pwcli@hku.hk

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

For participants for the BE-Prepared programme

Inclusion Criteria:

  • Adults with age ≥18 years
  • Residing in the community
  • Confirmed CAD diagnosis
  • Without a prior history of AMI; and
  • Access to an internet-enabled device

Exclusion Criteria:

  • Individuals who do not understand Cantonese
  • Individuals who have impaired communication, psychiatric problems or cognitive impairment (i.e., Abbreviated Mental Test ≤6)

For health providers participating in the SWOT analysis

Inclusion Criteria:

  • Full-time staff (doctors, nurses and social workers) in the Cardiac department of the study hospital who involve in providing care to cardiac patients

Exclusion Criteria:

  • Health care providers with part-time employment

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intervention group

Participants will receive usual care, access to the community-based health education initiative, and the five-week blended narrative intervention comprising one face-to-face workshop followed by four weekly web-based modules with nurse-facilitated interactive sessions.

The BE-Prepared programme consist of 2 components: a community-based health education initiative and a five week narrative intervention.

  1. The community-based health education component will utilise multiple media platforms, including Facebook, Instagram and YouTube, to provide AMI education to the general public with interactive and multimedia features incorporated. Regular online health seminars in live-streaming format will be held twice per quarter, featuring expert speakers in cardiovascular health-related topics.
  2. The narrative intervention will be delivered via a blended format, including a face-to-face workshop followed by four weekly web-based sessions that include pre-recorded educational materials and real-time interactions. Each module will be structured in two parts: first, a series of pre-recorded 3-5 minutes videos that introduce key information, and second, a real-time interactive session led by a nurse facilitator that consolidates learning.
Aktiver Komparator: Control group

Participants will receive usual care, comprising unstructured health education provided by the healthcare team, and access to the community-based health education initiative. They will not receive the structured five-week narrative intervention.

The usual care includes unstructured health education provided by the healthcare team and access to the community-based health education component of this project.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Care-seeking attitudes and beliefs for AMI symptoms, measured by the Acute Coronary Syndrome Response Index (ACSRI)
Zeitfenster: At baseline (T0), 3 months (T1) and 12 months (T2) post-programme

The Acute Coronary Syndrome Response Index-Chinese version (ACSRI-C) will be used to assess patients' attitudes and knowledge regarding AMI care-seeking. The ACSRI has good reliability (Cronbach's alphas: 0.76-0.82) and discriminant validity. It consists of a total of 33 questions divided into 3 scales measuring knowledge, attitudes, and belief. The attitudes subscale consists of 5 items, while the beliefs subscale consists of 7 items. Participants respond on a 4-point Likert scale. The higher subscale total scores (range for the attitudes subscale, 5-20; range for the beliefs subscale, 7-28) indicate more appropriate care-seeking attitudes and beliefs.

At baseline (T0), 3 months (T1) and 12 months (T2) post-programme

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Knowledge of AMI symptoms
Zeitfenster: At baseline (T0), 3 months (T1) and 12 months (T2) post-programme

AMI knowledge was measured using the knowledge subscale of the ACSRI-C. This subscale consists of 21 items to be answered dichotomously (yes/no). The correct items are summed (range, 0-21), and a higher total score represents greater knowledge

At baseline (T0), 3 months (T1) and 12 months (T2) post-programme
Perceived barriers to care-seeking, measured by the 10-item Perceived Barriers to Health Care-seeking Decision (PBHSD) scale
Zeitfenster: At baseline (T0), 3 months (T1) and 12 months (T2) post-programme

The 10-item Perceived Barriers to Health Care-seeking Decision (PBHSD) will be used to measure perceived barriers to care-seeking when patients experience AMI symptoms. Each item is rated on a 6-point Likert scalewith"1" indicating strongly disagree and "6" indicating strongly agree. The sum of scores on each item gives the overall score. The possible range of scores is 10-60, with higher scores indicating greater perceived barriers to seeking care.

At baseline (T0), 3 months (T1) and 12 months (T2) post-programme
Symptom onset-to-door (O2D) time among participants experiencing an AMI episode
Zeitfenster: 12 months following enrolment

O2D time, defined as the interval between the onset of ischaemic symptoms and hospital arrival will be determined through patient recall, using a benchmarking technique that associates symptom onset with daily routines to improve recall accuracy. The hospital arrival times will be verified from medical records.

12 months following enrolment
Ambulance use for transport to hospital among participants experiencing an AMI episode
Zeitfenster: 12 months following enrolment

The proportion of participants who used emergency ambulance services (versus other transport modes) to reach hospital during an AMI episode will be collected from reviewing medical records.

12 months following enrolment
In-hospital and 30-day major adverse cardiovascular and cerebrovascular events (MACCEs)
Zeitfenster: 12 months following enrolment

In-hospital and 30-day MACCEs, including cardiac- and non-cardiac-related mortality, malignant arrhythmias, recurrent AMI, unplanned coronary interventions or surgeries, new onset heart failure, and stroke, will be extracted from medical records according to the Standardized Data Collection for Cardiovascular Trials Initiative guidelines.

12 months following enrolment
Length of hospital stay among participants experiencing an AMI episode
Zeitfenster: 12 months following enrolment

Total length of the index hospital stay (in days) following an AMI episode, will be collected from reviewing medical records.

12 months following enrolment
Unplanned 30-day hospital readmissions among participants experiencing an AMI episode
Zeitfenster: 12 months following enrolment

The unplanned hospital readmissions within 30 days of discharge following an AMI episode, will be collected from reviewing medical records.

12 months following enrolment

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Reach of the BE-Prepared programme
Zeitfenster: Through study completion, 3 years since commencement

The reach of the target population will be assessed by recording the number of eligible participants and those who participate in the BE-Prepared programme.

Through study completion, 3 years since commencement
Adoption and engagement with the BE-Prepared programme
Zeitfenster: Over the 5-week intervention delivery period

Adoption will be assessed by documented attendance at the face-to-face session and the real-time online sessions. User engagement with programme materials will be tracked by the number of video views, the number of responses to embedded quizzes, and the average frequency and duration of viewing the programme materials.

Over the 5-week intervention delivery period
Implementation of the BE-Prepared programme
Zeitfenster: Over the 5-week intervention delivery period and upon completion

The implementation of the programme will be evaluated through assessing the adherence to the intended delivery protocol by two independent reviewers against a fidelity checklist, qualitative interviews with 30 participants and a self-developed 10-item participant satisfaction survey.

Over the 5-week intervention delivery period and upon completion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Polly Wai Chi Li, PhD, The University of Hong Kong, School of Nursing

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

1. Februar 2029

Studienabschluss (Geschätzt)

1. Februar 2029

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • UW 25-557

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .